Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

PLX holding history

Protalix BioTherapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

PLX overviewAll 13F holders of PLXFull Q2 2026 holdings

Shares (Q2 2026)
138,646
Value
$323.0K
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of PLX by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026138,646$323.0K<0.1%−126,889−47.8%ReducedHolders
Q1 2026265,535$576.2K<0.1%+3,015+1.1%AddedHolders
Q4 2025262,520$472.5K<0.1%+72,244+38.0%AddedHolders
Q3 2025190,276$422.4K<0.1%+115,126+153.2%AddedHolders
Q2 202575,150$111.2K<0.1%+73,063+3,500.9%AddedHolders
Q1 20252,087$5.34K<0.1%−16,091−88.5%ReducedHolders
Q4 202418,178$34.2K<0.1%+17,886+6,125.3%AddedHolders
Q3 2024292$298<0.1%−15−4.9%ReducedHolders
Q2 2024307$359<0.1%−67,649−99.5%ReducedHolders
Q1 202467,956$85.6K<0.1%−6,762−9.1%ReducedHolders
Q4 202374,718$133.0K<0.1%+37,658+101.6%AddedHolders
Q3 202337,060$61.5K<0.1%−14,980−28.8%ReducedHolders
Q2 202352,040$104.1K<0.1%+47,349+1,009.4%AddedHolders
Q1 20234,691$9.85K<0.1%+4,571+3,809.2%AddedHolders
Q4 2022120$164<0.1%−10,998−98.9%ReducedHolders
Q3 202211,118$11.0K<0.1%+10,998+9,165.0%AddedHolders
Q2 2022120$00.0%00.0%UnchangedHolders
Q1 2022120$00.0%00.0%UnchangedHolders
Q4 2021120$00.0%−2,194−94.8%ReducedHolders
Q3 20212,314$3.00K<0.1%+389+20.2%AddedHolders
Q2 20211,925$3.00K<0.1%−270−12.3%ReducedHolders
Q1 20212,195$10.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.